Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK’s CMA Fines Four On Nortriptyline

Accord, Alissa, Lexon And King Fined Over £3.4m In Total

Executive Summary

Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.

You may also be interested in...



CMA Sees Fine Over Nortriptyline Upheld In UK

The UK’s Competition and Markets Authority has welcomed a ruling upholding its finding that Lexon broke competition law in relation to nortriptyline, along with a connected £1.2m fine.

UK Court Declines To Back Phenytoin Fines

A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.

Two Admit Collusion On UK Nortriptyline

Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.

Related Content

Topics

UsernamePublicRestriction

Register

GB149670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel